We are live on ! Find out more
JAZZ icon

Jazz Pharmaceuticals
JAZZ

234 hedge funds and large institutions have $3.41B invested in Jazz Pharmaceuticals in 2013 Q2 according to their latest regulatory filings, with 234 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

57% less call options, than puts

Call options by funds: $26.3M | Put options by funds: $60.9M

Holders
234
Holders Change
+234
Holders Change %
–
% of All Funds
7.64%
Holding in Top 10
10
Holding in Top 10 Change
+10
Holding in Top 10 Change %
% of All Funds
0.33%
New
234
Increased
–
Reduced
–
Closed
–
Calls
$26.3M
Puts
$60.9M
Net Calls
-$34.6M
Net Calls Change
-$34.6M

Top Buyers

No buyers this quarter

Top Sellers

No sellers this quarter
Name Holding Trade Value Shares
Change 		Change in
Stake
JHIU
1
Janus Henderson Investors US
Colorado
$331M +$294M +4,815,145 New
Fidelity Investments
2
Fidelity Investments
Massachusetts
$262M +$233M +3,810,197 New
PI
3
Putnam Investments
Massachusetts
$249M +$221M +3,619,403 New
KKRC
4
Kohlberg Kravis Roberts & Co
New York
$219M +$195M +3,185,058 New
Vanguard Group
5
Vanguard Group
Pennsylvania
$180M +$160M +2,614,309 New
AllianceBernstein
6
AllianceBernstein
Tennessee
$105M +$92.9M +1,520,620 New
SFM
7
Systematic Financial Management
New Jersey
$89.2M +$79.3M +1,297,757 New
Franklin Resources
8
Franklin Resources
California
$83.2M +$74M +1,210,791 New
BIT
9
BlackRock Institutional Trust
California
$82.9M +$73.8M +1,206,700 New
Calamos Advisors
10
Calamos Advisors
Illinois
$81.7M +$72.7M +1,188,602 New
BFA
11
BlackRock Fund Advisors
California
$69.4M +$61.7M +1,010,174 New
T. Rowe Price Associates
12
T. Rowe Price Associates
Maryland
$67.9M +$60.4M +988,200 New
PC
13
Paulson & Co
New York
$66.2M +$58.9M +963,000 New
State Street
14
State Street
Massachusetts
$65.8M +$58.5M +957,138 New
Invesco
15
Invesco
Georgia
$62.5M +$55.6M +910,006 New
Bank of New York Mellon
16
Bank of New York Mellon
New York
$51.5M +$45.8M +749,224 New
TCIM
17
TIAA CREF Investment Management
New York
$50.6M +$45M +736,280 New
CCM
18
Century Capital Management
Massachusetts
$50.2M +$44.6M +729,994 New
CCI
19
Columbus Circle Investors
$46.3M +$41.1M +673,008 New
Ameriprise
20
Ameriprise
Minnesota
$46M +$40.9M +669,830 New
RIM
21
RS Investment Management
California
$45.7M +$40.7M +665,603 New
Northern Trust
22
Northern Trust
Illinois
$37.6M +$33.4M +546,404 New
Wells Fargo
23
Wells Fargo
California
$35.8M +$31.8M +520,342 New
D.E. Shaw & Co
24
D.E. Shaw & Co
New York
$32M +$28.5M +466,257 New
TCB
25
Thoma Cressey Bravo
Illinois
$31.6M +$28.1M +459,130 New
1
2 3 4 5

JAZZ Hedge Fund Activity: Q2 2013 in Review

234 of the 3,064 institutional investors tracked by Wall St. Rank reported a position in Jazz Pharmaceuticals (JAZZ) for Q2 2013, worth a combined $3.41B.

Buyers outnumbered sellers: 234 funds opened new JAZZ positions and 0 closed out — a net gain of 234 holders — while 0 added to existing stakes and 0 trimmed.

  • 234 institutional investors held Jazz Pharmaceuticals (JAZZ) as of Q2 2013, up from 0 in Q1 2013.
  • Funds reported $3.41B of Jazz Pharmaceuticals stock for Q2 2013.
  • 234 funds opened new Jazz Pharmaceuticals positions in Q2 2013 and 0 closed out, a net change of +234 holders.

Based on aggregated 13F filings for Q2 2013.